Kennedy Ferruggia, Associate Editor

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Shifting federal vaccine guidance fuels parent confusion and uneven care, as clinicians lean on scientific consensus.

The FDA targets mass-marketed compounded GLP-1 drugs, warning of safety risks and deceptive ads as enforcement ramps up for weight-loss injectables.

The FDA declines to review Moderna’s mRNA flu vaccine filing over comparator choice, despite positive phase 3 results.

Learn how pharmacists cut GLP-1 costs, streamline prior authorizations, guide safe switches, and bust social media myths for lasting adherence.

Host Craig Beavers explores why US blood pressure control still lags despite proven treatments.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation setting.

Bangladesh reports fatal Nipah case linked to raw date palm sap; experts say spread stays limited as vaccines and rapid tests advance.

Learn how workplace triggers, long flares, and new therapies reshape pharmacist-led care for chronic hand eczema.

Ongoing variation in vaccine schedule implementation requires pharmacists and clinicians to collaborate closely, reinforce evidence-based care, and monitor vulnerable populations for gaps in immunization coverage.

Pharmacists play a vital role in countering GLP-1 misinformation.

India has confirmed 2 Nipah infections in West Bengal as surveillance tracks 196 contacts with no spread, with the World Health Organization outlining symptoms, transmission, and response measures.

Changes to the federal childhood vaccine schedule have created confusion and variation in practice, placing added responsibility on clinicians and pharmacists to educate patients and ensure evidence-based care.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

COVID-19 significantly impacts diagnosis rates for depression, asthma, and osteoporosis, revealing health care inequities and the need for improved monitoring.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Pharmacists play a critical role in improving access to and affordability of GLP-1 therapies.

Research reveals that patients with asthma who experience symptoms of depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.

RegeneCyte's HPC therapy shows promise in treating long COVID symptoms, with 85% of patients reporting fatigue relief.

The FDA approved the first dual-agent eye drops for presbyopia, offering a groundbreaking solution for age-related near vision loss.

David Shusterman, MD, reveals how reducing alcohol enhances GLP-1 therapy, improving insulin regulation, kidney health, and overall metabolic outcomes.

GLP-1 receptor agonist effectiveness and tolerability can be significantly improved through targeted pharmacist counseling on alcohol reduction.

New research reveals how specific gut bacteria in infants may reduce the risk of allergies and asthma, offering potential preventive strategies.

Reducing alcohol intake alongside GLP-1 therapy may significantly improve outcomes for patients with obesity or diabetes risk.

Research reveals COVID-19's lasting effects on brain health, highlighting cognitive impairments in patients with long COVID even after recovery.

Rocatinlimab shows promise in treating moderate-to-severe atopic dermatitis, offering significant symptom relief.

Insufficient sleep significantly impacts life expectancy, highlighting the need to prioritize quality rest for better health and longevity.

The FDA approves gepotidacin as a groundbreaking oral treatment for uncomplicated urogenital gonorrhea.

Heidi De Souza discusses strategies to enhance RSV vaccine uptake among older adults, emphasizing awareness, coadministration patterns, and public health efforts.

The glucagon-like peptide-1 (GLP-1) receptor agonist medications evaluated included semaglutide, tirzepatide, and liraglutide.